Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0043167 (pertussis)
 19,595 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Intrafamilial spread of pertussis was evaluated in 21 families (97 individuals) of patients with whooping cough diagnosed by culture or by ELISA serology. During follow-up (average six months), an infectivity rate of 83% was established by an ELISA within these families. However, 46% of the secondary cases were asymptomatic. Most of the asymptomatic cases were in adults or vaccinated children. Unvaccinated infants had classic whooping cough and were exposed to pertussis by their vaccinated siblings or parents. The incidence of classic symptoms of pertussis decreased with age, and atypical pertussis was usually culture negative but rapidly diagnosed by measurement of the IgM- and IgA-class antibodies by ELISA.
 ...
PMID:Intrafamilial spread of pertussis. 688

Adverse reactions and anti-DTP antibody responses were compared between DTP- or DTP-inactivated-polio-vaccinated children. The material consisted of 380 children whose adverse reactions were registered by detailed questionnaires given to the parents. IgG-, IgM- and IgA-anti-DTP antibodies of 42 children were quantified using enzyme-linked immunosorbent assay (ELISA). Fever, restlessness and local reactions were the most frequent adverse reactions observed. DTP-polio vaccine induced significantly more restlessness than DTP. This was the only significant difference in adverse reactions between the vaccines. An enhancement of IgG-anti-DTP antibody responses at the age of 6 months was observed in the DTP-polio group. The enhancement was transient in antitoxin responses but still present in pertussis antibodies at 8 months of age. Very low and mostly undetectable levels of IgM- and IgA-anti-DTP antibodies were observed in both groups.
 ...
PMID:DTP and DTP-inactivated polio vaccines: comparison of adverse reactions and IGG, IGM and IGA antibody responses to DTP. 698 54

The pertussis vaccination programme was started in Finland in 1952. Since then the incidence of the disease has decreased. No major epidemics have occurred during the last two decades. The majority of the patients with pertussis are children of school age. Their disease is characterized by prolonged cough without whooping and it is difficult to diagnose. The patients with atypical pertussis are, however, the major reservoir for transmission of the disease to young infants, in whom it can be serious. Recently developed ELISA for measuring antipertussis IgM and IgA antibodies is a valuable aid in the diagnosis of these cases. Pertussis vaccination has been a subject of considerable controversy in recent years. The vaccine used in Finland has proved to be safe and effective. This observation emphasizes the need for careful comparison of the vaccines used in different countries.
 ...
PMID:Current status of pertussis and pertussis vaccination in Finland. 717 Dec 32

Incidental to a phase II study of acellular and whole-cell pertussis vaccines involving 342 infants who were clinically observed from birth until the age of 9 months, subclinical pertussis was retrospectively diagnosed in 10 infants on the basis of serological evidence. IgG and IgA to filamentous haemagglutinin (FHA), pertussis toxin (PT) and agglutinogens 2 and 3 (AGG2, 3) were assayed by enzyme-linked immunosorbent assay (ELISA) in serum obtained at birth and at 2, 4, 6 and 9 months of age. All 10 infants had > or = 4-fold rises in at least two different pertussis IgG antibodies. Nine of the 10 infants had > or = 4-fold increases in all three IgG antibodies measured. One infant had > or = 4-fold increases in IgG-FHA and IgG-AGG2,3 but not IgG-PT. Seven infants had raised IgA antibodies to PT and FHA and 4 infants had raised IgA antibodies to AGG2,3. Subclinical infection provoked differing degrees of antibody production in response to multiple antigens. Subclinical infection was detected in both unvaccinated infants (4) and in infants who had been vaccinated from 2 months of age with either acellular (4) or whole-cell vaccines (2). Subjects were 8 months of age or younger and only 1 had completed primary vaccination. Other infections of infancy were commonly detected; 4 infants had upper respiratory disease about the time of subclinical pertussis. None had a household member with symptomatic pertussis. Likelihood of subclinical infection was related to significantly lower levels of maternally acquired pertussis IgG-AGG2,3 antibodies but not associated with infants' nutritional status.
 ...
PMID:Subclinical pertussis in incompletely vaccinated and unvaccinated infants. 748 85

The microagglutination assay is a useful method for the diagnosis of B. pertussis infections. In a group of 30 patients with culture proven pertussis 27 (90%) had > or = fourfold increases in titers between acute and convalescent phase serum specimens. The microagglutination test offers several advantages over other more sophisticated B. pertussis antibody tests: only 50 microliters of serum is required, it is a standardized test, which doesn't require specialized technical expertise or equipment, it is easy to perform and good results are noted in a broad age range of patients. Disadvantages of the microagglutination test are: two separate serum specimens are necessary (acute and convalescent phase), the test does not differentiate IgA and IgG antibodies and the temporal association with recent immunization can lead to false positive results. In our opinion the microagglutination test is a useful method for the diagnosis of B. pertussis infections. This is especially true in cases where more sophisticated serologic tests such as ELISA can not be performed immediately but physicians and patients expect to get a result quickly.
 ...
PMID:[The microagglutination test--a simple and sensitive procedure for serodiagnosis of pertussis infections]. 750 Jun 3

Degranulation of eosinophils and release of toxic granule proteins play key roles in allergic diseases such as bronchial asthma. However, the intracellular signaling mechanisms that trigger eosinophil degranulation remain unclear. In this study, we investigated protein tyrosine kinase (PTK) involvement in the degranulation of human blood eosinophils induced by immobilized Ig. Eosinophils stimulated with Sepharose beads coated with secretory IgA (slgA) or IgG showed rapid increases in the tyrosine phosphorylation of intracellular proteins with molecular masses of 50 to 56, 73, 78, 100, and 105 kDa. The Ig-induced phosphorylation response was not affected by pertussis toxin, a known inhibitor of Ig-dependent eosinophil activation. The tyrosine kinase inhibitors genistein and herbimycin A inhibited both the tyrosine phosphorylation and degranulation responses of eosinophils induced by sIgA- or IgG-coated beads. In contrast, eosinophil degranulation induced by PMA was not affected by genistein. Treatment of eosinophils with the protein phosphatase inhibitor pervanadate induced the phosphorylation of a similar set of intracellular proteins as well as cellular degranulation. Pervanadate also stimulated an increase in phosphoinositide hydrolysis, which was consistent with the activation of a phospholipase C-gamma isoform by this stimulus. Genistein pretreatment blocked the Ig-induced phospholipase C activation, providing evidence for PTK involvement in this reaction. These findings indicate that a PTK-dependent signaling pathway plays an important role in triggering the degranulation responses of human eosinophils to immobilized sIgA and IgG.
 ...
PMID:Tyrosine phosphorylation is required for eosinophil degranulation induced by immobilized immunoglobulins. 760 11

Pertussis is well controlled in the United States by routine childhood immunization. In contrast, this disease is endemic and epidemic in Germany because routine immunization has not been implemented. To gain information relating to the epidemiology of Bordetella pertussis infections, we examined the prevalence and magnitude of B. pertussis agglutinins and of IgG and IgA antibodies (detected by enzyme-linked immunosorbent assay) to four B. pertussis antigens--lymphocytosis-promoting factor, filamentous hemagglutinin, pertactin, and fimbriae-2--in the sera of 119 American university students and 119 German military recruits of similar age. Geometric mean titers of agglutinins and geometric mean values for IgG antibodies to the four antigens were two- to threefold higher in sera from the American students than in sera from German recruits. In contrast, the geometric mean IgA values and the percentage of subjects with detectable IgA antibodies to the four antigens were similar in the two populations. Since IgA antibody results mainly from infection and not from immunization, our data suggest that B. pertussis infections are common among both American and German young adults despite the marked difference in rates of clinical pertussis in the two countries.
 ...
PMID:Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. 762 9

The intranasal (i.n.) immunization of mice with Bordetella pertussis filamentous haemagglutinin (FHA) either as a solution or incorporated in biodegradable microparticles induced very similar immune responses. Both resulted in strong systemic IgG responses to FHA and good levels of anti-FHA IgG and IgA in the lungs of immunized mice. In comparison, the intraperitoneal (i.p.) immunization of mice with FHA, as a solution, engendered anti-FHA antibody responses which were stronger for serum IgG, similar for lung IgG and lower for lung IgA. The anti-FHA antibody levels, as measured by immunosorbent assay, were shown to correlate with their functional activity in the blocking of B. pertussis adhesion to HeLa tissue-culture cells. All three forms of immunization appeared to stimulate T-cell responses as assessed by in vitro antigen-specific spleen cell proliferation and IL-2 secretion indicative of a Th1 type response, however, cells from i.p. immunized mice only secreted low levels of IL-5. All three methods of FHA immunization provided mice with significant protection against subsequent aerosol challenge with virulent B. pertussis. Mice which had been immunized intra-nasally eliminated the bacteria from their lungs slightly more rapidly than i.p. immunized mice, demonstrating the efficacy of intranasal administration of FHA in solution and in the more practical biodegradable microparticle form.
 ...
PMID:Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. 763 14

We examined the capacity of a genetically detoxified derivative of pertussis toxin (PTX), PT-9K/129G, to act as a mucosal adjuvant for an intranasally (i.n.) administered tetanus vaccine. Groups of mice were immunized i.n. with the nontoxic C-terminal 50-kDa portion of tetanus toxin (fragment C [Frg C]) either alone or mixed with PT-9K/129G, PTX, or cholera toxin (CT) or were immunized subcutaneously (s.c.) with an equivalent amount of Frg C adsorbed to alhydrogel. In response to a single immunization, mice receiving Frg C plus PT-9K/129G or CT i.n. and parenterally immunized mice developed high-titer (> 20,000) anti-Frg C antibodies, whereas mice immunized i.n. with Frg C plus PTX or with Frg C alone seroconverted only after being boosted. The serum anti-Frg C response was dominated by immunoglobulin G1 (IgG1) in mice immunized with Frg C plus PT-9K/129G, with Frg C plus PTX, or s.c. In contrast, IgG1, IgG2a, and IgG2b contributed almost equally to the Frg C response when CT was the adjuvant. Anti-Frg C IgE was detected only in the sera of mice immunized i.n. with Frg C plus PTX and immunized s.c. with Frg C plus alhydrogel. High levels of IgA antibodies were present in nasal lavage fluid from mice immunized i.n. with Frg C plus PT-9K/129G, PTX, or CT but not in that from mice given Frg C alone i.n. or parenterally. The mucosal adjuvanticity of PT-9K/129G was manifested in inbred as well as outbred mice. A single i.n. dose of Frg C plus either PT-9K/129G or PTX (with high specific activity) was sufficient to protect all immunized mice from tetanus toxin challenge, in contrast to the case for mice that received Frg C alone i.n. We conclude that the pertussis toxin analog PT-9K/129G, which is devoid of ADP-ribosyltransferase activity, is a potent mucosal adjuvant for vaccines delivered via the respiratory tract.
 ...
PMID:A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. 776 87

To evaluate the role of adults in the transmission of pertussis during an epidemic, persons presenting with unexplained cough to ambulatory care clinics were evaluated for evidence of pertussis infection. Nasopharyngeal specimens for culture and serum samples for IgG and IgA antibodies to filamentous hemagglutinin and pertussis toxin antigens of Bordetella pertussis were obtained. Thirty-eight adults were enrolled in the study; 10 (26%) had serologic evidence of B. pertussis infection. Clinical findings were not significantly different among persons with and without evidence of pertussis infection. Pertussis should be considered in the differential diagnosis of persistent cough in all age groups. Future use of new acellular pertussis vaccines in adults may substantially impact the control of the infection.
 ...
PMID:Pertussis infection among adults during the 1993 outbreak in Chicago. 776 11


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>